Continuous activation of mTORC2 molecules in hepatocytes produces sphingolipid glucosylceramide to stimulate ROS generation, which can ultimately lead to HCC development; and targeting mTOR is a useful strategy for cancer treatment [11–13]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.